AU3589701A - Orally administered controlled delivery system for once daily administration of ciprofloxacin - Google Patents

Description

WO 01/64183 PCT/IBO1/00279 ORALLY ADMINISTERED CONTROLLED DELIVERY SYSTEM FOR ONCE DAILY ADMINISTRATION OF CIPROFLOXACIN 5 BACKGROUND OF THE INVENTION The present invention relates to a pharmaceutical composition in the form of tablets or capsules which provides a combination of spatial and temporal control of drug delivery, specifically for the drug ciprofloxacin, to a patient for effective therapeutic results. The pharmaceutical composition comprises 10 ciprofloxacin, a gas generating component, a swelling agent, and at least one of either a viscolyzing agent and a gelling agent. The swelling agent belongs to a class of highly absorbent compounds commonly referred to as superdisinte grants. This class of compounds includes, for example, cross-linked polyvinyl pyrrolidone and cross-linked sodium carboxymethylcellulose. The viscolyzing 15 agent is a highly viscous material which upon contact with gastric fluid entraps the gas produced by the gas generating component. The viscolyzing agent comprises, for example, a carbohydrate gum, e.g., xanthan gum or a cellulose ether, e.g., hydroxypropyl methylcellulose (methocel). The gelling agent is preferably a cross-linkable gelling agent, such as a water soluble salt of one or 20 more polyuronic acids, e.g., sodium alginate. The improved controlled drug delivery system of the present invention is designed to deliver effectively ciprofloxacin to a patient over a specific time period (temporal control) and from a particular portion of the patient's gastrointestinal tract (spatial control). The improved controlled drug delivery 25 system avoids dose dumping and results in the most therapeutic administration of ciprofloxacin to a person. -1 - WO 01/64183 PCT/IBO1/00279 It is well known to those skilled in the art that for ailments requiring multiple doses of a particular drug, the blood levels of a drug need to be maintained above its minimum effective level and below its minimum toxic level in order to obtain the desired therapeutic effects, to avoid undesired toxic effects, 5 and to minimize side effects. When the blood levels of a drug are in this range, the drug is eliminated from the body at a particular rate. A controlled drug delivery system is usually designed to deliver the drug at this particular rate; safe and effective blood levels are maintained for a period as long as the system continues to deliver the drug at this rate. Controlled drug delivery usually results 0 in substantially constant blood levels of the active ingredient as compared to the uncontrolled fluctuations observed when multiple doses of quick releasing conventional dosage forms are administered to a patient. Controlled drug delivery results in optimum therapy, and not only reduces the frequency of dosing, but may also reduce the severity and frequency of side effects. 5 The above basic concepts of controlled drug delivery are well known to those skilled in the art. Considerable efforts have been made in the last decades to develop new pharmaceutically viable and therapeutically effective controlled drug delivery systems. Attention has been focused particularly on orally administered controlled drug delivery systems because of the ease of ?0 administration via the oral route as well as the ease and economy of manufacture of oral dosage forms such as tablets and capsules. A number of different oral controlled drug delivery systems based on different release mechanisms have been developed. These oral controlled drug delivery systems are based on different modes of operation and have been variously named, for -2- WO 01/64183 PCT/IBO1/00279 example, as dissolution controlled systems, diffusion controlled systems, ion exchange resins, osmotically controlled systems, erodible matrix systems, pH independent formulations, swelling controlled systems, and the like. An orally administered controlled drug delivery system encounters a wide 5 range of highly variable conditions, such as pH, agitation intensity, and composition of the gastrointestinal fluids as it passes down the gastrointestinal tract. Ideally, an oral controlled drug delivery system will deliver the drug at a constant and reproducible rate in spite of the varying conditions. Considerable efforts have therefore been made to design oral controlled drug delivery systems 10 that overcome these drawbacks and deliver the drug at a constant rate as it passes down the gastrointestinal tract. It is well known to those skilled in the art that a drug may not be absorbed uniformly over the length of the gastrointestinal tract, and that drug absorption from the colon is usually erratic and inefficient. Also, certain drugs are absorbed 15 only from the stomach or the upper parts of the small intestine. Furthermore, an important factor which may adversely affect the performance of an oral controlled drug delivery system is that the dosage form may be rapidly transported from more absorptive upper regions of the intestine to lower regions where the drug is less well absorbed. Therefore, in instances where the drug is 20 not absorbed uniformly over the gastrointestinal tract, the rate of drug absorption may not be constant in spite of the drug delivery system delivering the drug at a constant rate into the gastrointestinal fluids. More particularly, in instances where a drug has a clear cut "absorption window," i.e., the drug is absorbed only from specific regions of the stomach or upper parts of the small intestine, it may -3- WO 01/64183 PCT/IBO1/00279 not be completely absorbed when administered in the form of a typical oral controlled drug delivery system. It is apparent that for a drug having such an "absorption window," an effective oral controlled drug delivery system should be designed not only to deliver the drug at a controlled rate, but also to retain the 5 drug in the upper parts of the gastrointestinal tract for a long period of time. U.S. Patent No. 5,651,985, assigned to Bayer AG, discloses a composition comprising - a pharmacologically active compound, a pharmaceutically acceptable auxiliary, polyvinylpyrrolidone, and a methacrylic acid polymer having an acidic number between 100 and 1200 mg of KOH/g of 10 polymer solid substance. Optionally, the composition also comprises a gas forming additive. The composition absorbs many times its weight of acidic water and forms a highly swollen gel of high mechanical and dimensional stability. The gel forming agent should be sufficient so that after administration it can swell up to a size which prevents passage through the pylorous for a relatively long time. 15 At least 30% by weight and up to 90% by weight of the composition comprises the polymers, and thus dosage forms containing a high dose medicament would be large and inconvenient for oral administration. Generally, in the field of controlled drug delivery systems, it is known that in order to make a particular drug available as a once-daily tablet or capsule, it 20 is necessary to experiment and invent with the particular drug together with specific excipients. Thus, what particular excipients and in what particular relative amounts may work for a particular active ingredient or drug, to make it available on a once-daily basis, will likely not work for another drug. -4- WO 01/64183 PCT/IBO1/00279 Nishioka et al. (JP 06024959) is a Japanese patent publication wherein an attempt is made to cause the release of ciprofloxacin over a longer period of time by causing the tablet containing ciprofloxacin to remain suspended in the stomach. The release period obtained by the Nishioka tablet is so slow that only 5 46% of the Nishioka tablet is dissolved after 24 hours (see plot). The practical and significant effect of this slow dissolution is that the Nishioka formulation would not be effective as a "once daily" ciprofloxacin formulation. Accordingly, none of the oral controlled drug delivery systems heretofore described is completely satisfactory for the purpose of providing a once daily 10 formulation for the controlled release of ciprofloxacin. OBJECTS OF THE PRESENT INVENTION It is an object of the present invention to provide a pharmaceutical composition in the form of tablets or capsules which constitutes a once daily formulation for the controlled release of ciprofloxacin that: 15 a. generates and entraps a gas in a hydrated matrix upon contact with an aqueous medium or gastric fluids, and which retains a substantially monolithic form in the stomach, b. provides increased gastric residence and thereby a longer period of residence of the drug delivery system in the gastrointestinal 20 tract, c. delivers the drug at a controlled rate such that the drug is delivered over a period of time which is the same as or less than the period -5- WO 01/64183 PCT/IBO1/00279 of residence of the delivery system in the absorptive regions of the gastrointestinal tract, and d. provides, as compared to other oral controlled drug delivery systems, increased absorption of a drug that is absorbed largely 5 from the upper parts of the gastrointestinal tract. It is also an object of the present invention to provide a once daily formulation for the controlled release of ciprofloxacin that maintains its physical integrity, i.e., remains intact or substantially gains a monolithic form when contacted with an aqueous medium, even when the quantity of medicaments is 10 large, and wherein the proportion of polymers is small compared to other components of the system. It is a further object of the present invention to provide a once daily formulation for the controlled release of ciprofloxacin that incorporates a high dose medicament without the loss of any of its desirable attributes, as listed above, such that the system is of an acceptable size for oral 15 administration. SUMMARY OF THE INVENTION The present invention provides a novel pharmaceutical composition in the form of tablets or capsules which composition constitutes an orally administered once daily formulation for the controlled release of ciprofloxacin. The pharma 20 ceutical composition comprises ciprofloxacin, a gas generating component, a swelling agent (e.g., cross-linked polyvinylpyrrolidone or cross-linked sodium carboxymethylcellulose), at least one of either a viscolyzing agent (e.g., a carbohydrate gum such as xanthan gum or a cellulose ether such as hydroxy propyl methylcellulose), and a gelling agent (e.g., sodium alginate). -6- WO 01/64183 PCT/IBO1/00279 Preferably, the inventive oral controlled drug delivery system which is a pharmaceutical composition in the form of tablets or capsules comprises a pharmaceutically effective amount of ciprofloxacin, about 0.1% to about 8% by weight of at least one of a viscolyzing agent and a gelling agent, about 5% to 5 about 15% by weight of the gas generating component, and about 3% to about 15% by weight of the swelling agent. More preferably, the amount of at least one of the viscolyzing agent and the gelling agent ranges from about 0.2% to about 5% and the amount of the swelling agent ranges from about 3% to about 15%. 0 Even more preferably, the present invention is related to a once-daily tablet formulation for oral administration in humans for the controlled release of ciprofloxacin comprising a pharmaceutically effective amount of ciprofloxacin, about 0.2% to about 0.5% sodium alginate, about 0.5 to about 2.0% xanthan gum, about 10.0% to about 25% sodium bicarbonate, and about 5.0% to about 5 20% cross-linked polyvinylpyrrolidone, said percentages being w/w of the composition, wherein the weight ratio of sodium alginate to xanthan gum is between about 1:1 to about 1:10. The swelling agents used herein (cross-linked polyvinylpyrrolidone or cross-linked sodium carboxymethylcellulose) belong to a class of compounds 20 known as super-disintegrants which usually function to promote disintegration of a tablet by absorbing large amounts of water and thereby swelling. This expansion, as well as hydrostatic pressure, cause the tablet to burst. In a tablet which also comprises a gas generating component (which may actually be a gas -7- WO 01/64183 PCT/IBO1/00279 generating couple), one would expect the tablet to disintegrate instantly upon contact with aqueous fluid, if not blow apart. Remarkably, it has been found that in the presence of an instantly acting viscolyzing agent and/or a gelling agent, the generated gas is entrapped and the super-disintegrant acts as a swelling 5 agent which swells to, preferably, at least twice its original volume. Thus, the combination of the gas generating component, the swelling agent which is actually a super-disintegrant, and the viscolyzing agent or a gelling agent permit the formulation to act as a controlled drug delivery system. Additionally, with the passage of time, the gelling agent and/or the viscolyzing agent produces a 10 cross-linked three-dimensional molecular network resulting in a hydrodynam ically balanced system that is retained in the stomach and releases the drug over a sustained period of time. Surprisingly, it has been found that a tablet or capsule formed from the formulation of the present invention is retained for longer periods of time in the 15 stomach (spatial control) than previously known hydrophilic matrix tablets, floating capsules and bioadhesive tablets when these systems are administered with food. The formulation of the present invention results in release of the drug into the more absorptive regions of the gastrointestinal tract, i.e., into the stomach and the small intestine rather than into the large intestine where drug 20 absorption is poor or erratic. Thus, one may expect that if the drug is released at a constant and controlled rate, it will also be absorbed at a more or less constant rate. Even more surprisingly, it has been found that even for a drug that is absorbed only from the upper gastrointestinal tract (i.e., from the stomach down -8- WO 01/64183 PCT/IBO1/00279 to the jejunum), such as ciprofloxacin, the present formulation provides the desired absorption at a rate such that effective plasma levels are maintained for a prolonged duration and the formulation is especially suitable for once-daily administration (temporal control). Moreover, the formulation provides increased 5 absorption of the drug as compared to other oral controlled drug delivery systems such as hydrophilic matrix tablets and floating capsules. This is achieved by adjusting the time period of release for the drug so that it is about the same as or less than the retention time of the tablets at the site of absorption. Thus, the tablet or capsule is not transported past the "absorption 10 window" prior to releasing all of the drug, and maximum bioavailability is attained. BRIEF DESCRIPTION OF THE DRAWINGS Fig. 1 is a graph illustrating mean serum concentration vs. time for the drug ciprofloxacin free base and ciprofloxacin HCI when incorporated in the oral 15 controlled drug delivery system as compared to the presently marketed Cipro TM (Bayer Corp.) immediate release tablets. Figs. 2 and- 3 are graphs illustrating mean plasma concentration vs. time for ciprofloxacin free base when incorporated in the oral controlled drug delivery system of the present invention as compared to CiproTM immediate release 20 tablets under fed and fasting conditions. DETAILED DESCRIPTION OF THE INVENTION According to the present invention, the formulation of the present inven tion includes ciprofloxacin, a swelling agent, and at least one of either a -9- WO 01/64183 PCT/IBO1/00279 viscolyzing agent and a gelling agent. Together these components form a hydrated gel matrix. The formulation further comprises a gas generating component such that a gas (generally CO 2 but in some cases SO 2 ) is generated in a controlled manner and is entrapped in the hydrated gel matrix. The swelling 5 agent which belongs to the class of compounds known as superdisintegrants, absorbs large amounts of fluid and causes the matrix to swell significantly. The gas generated by the gas generating component also causes matrix expansion. However, in the present invention, swelling of the matrix is controlled by the viscolyzing agent and/or the gelling agent, which acts both as a swelling and a 10 drug release controlling agent. The characteristics of the hydrated gel matrix can be modified by altering the ratios and amounts of the swelling agent, the viscolyzing agent and/or the gelling agent, and the gas generating component without loss of physical integrity of the hydrated gel system. The composition can thus be designed to 15 obtain the optimal rate of release of the ciprofloxacin. It has also been found that such a composition when administered with food is retained for longer periods in the stomach, and thereby in the gastrointestinal tract without loss of its physical integrity. The generated gas influences the drug delivery from the tablets or 20 capsules in ways that are currently not well understood. For example, factors that may influence drug delivery include: -10- WO 01/64183 PCT/IBO1/00279 a. the presence of entrapped gas within the matrix can affect the diffusion path length of the drug and thus exerts a release controlling effect; b. the presence of entrapped gas within the matrix can affect the rate 5 of surface erosion of the hydrated gel matrix and thus exerts both a hydrodynamic and a release controlling effect; c. the expanding pressure and the presence of the gas affects the internal structure of the hydrated gel and thus exerts both a hydrodynamic and a release controlling effect; and, 10 d. the presence of entrapped gas and its expanding pressure affects the influx of the acidic gastric fluid through the pores of the matrix and thus exerts a release-controlling effect. It should be realized that gas generated in a small volume within the matrix can exert a high pressure. If this exceeds the capillary pressure due to 15 the surface tension of the aqueous fluid, then it will cause the aqueous fluid in a pore to be pushed by the gas allowing the gas to expand until the internal gas pressure equals the capillary pressure. This phenomenon thus would affect the rate of hydration of the matrix and have a role in determining the rate of release of the drug. In systems which cross-link, it will also have an influence on the 20 developing gel structurization. The various components of the novel formulation will now be described in more detail. - 11 - WO 01/64183 PCT/IBO1/00279 DRUG According to the present invention, the pharmaceutical composition is in the form of tablets or capsules that provide a controlled rate of delivery (i.e., temporal control, specifically) of ciprofloxacin. The present invention is partic 5 ularly suitable for controlled rate of delivery of a drug such as ciprofloxacin that does not show uniform dissolution and absorption characteristics throughout the length of the gastrointestinal tract. The novel pharmaceutical composition is most suited for controlled delivery of drugs that are absorbed only from the upper parts of the gastro 10 intestinal tract with a specific absorption window (i.e., spatial control), i.e., ciprofloxacin (which is absorbed only from the region extending from the stomach to the jejunum). The pharmaceutical composition is particularly suitable for ciprofloxacin because the absorption of the drug is dependent on its solubility characteristics. Ciprofloxacin dissolves at lower pH values and therefore the 15 "absorption window" is predominantly in the stomach or upper parts of the small intestine. In the case of drugs such as ciprofloxacin, the tablet is not transported past the "absorption window" prior to releasing all the drug so that maximum bioavailability can be attained. Ciprofloxacin itself or its pharmaceutically acceptable salt or ester may be 20 used in the present invention. The amount of ciprofloxacin to be used in the composition is that which is typically administered for a given period of time. According to the present invention, the pharmaceutical composition can incorporate a high dose medicament. Accordingly, the amount of ciprofloxacin - 12- WO 01/64183 PCT/IBO1/00279 to be used in the present invention typically ranges from about 0.5 mg up to about 1200 mg. GAS GENERATING COMPONENT The gas generating component comprises a substance known to produce 5 gas upon contact with gastric fluid. Examples of the gas generating component that may be used in the present invention include carbonates, such as calcium carbonate, potassium carbonate or sodium carbonate, and bicarbonates such as sodium hydrogen carbonate. The gas generating component interacts with an acid source triggered by 10 contact with water or simply with gastric fluid to generate carbon dioxide that gets entrapped within the hydrated gel matrix of the swelling composition. The gas generating component such as carbonates and bicarbonates may be present in amounts from about 5% to about 15%, by weight of the composition. These salts can be used alone or in combination with an acid source as 15 a couple. The acid source may be one or more of an edible organic acid, a salt of an edible organic acid, or mixtures thereof. Examples of organic acids that may be used as the acid source in the present invention include, for example: citric acid or its salts such as sodium citrate or calcium citrate; malic acid, tartaric acid, succinic acid, fumaric acid, maleic acid, or their salts; ascorbic acid or its 20 salts such as sodium or calcium ascorbate; glycine, sarcosine, alanine, taurine, glutamic acid, and the like. The organic acid salts that may be used as the acid source in the present invention include, for example, a mono-alkali salt of an organic acid having more than one carboxylic acid functional group, a bialkali - 13- WO 01/64183 PCT/IBO1/00279 metal salt of an organic acid having more than two carboxylic acid functional groups, and the like. The acid source may be present in an amount from about 0.5% to 15% by weight, preferably from about 0.5% to about 10% by weight, and more preferably from about 0.5 % to about 5% by weight, of the total weight of 5 the composition. SWELLING AGENT According to the present invention, the pharmaceutical composition comprises a swelling agent which is capable of swelling to greater than its original volume when coming into contact with an aqueous fluid, such a 10 gastrointestinal fluid. The preferred swelling agent is cross-linked polyvinyl pyrrolidone; other swelling agents include cross-linked carboxymethylcellulose sodium and the like. These compounds belong to the class of compounds known as super-disintegrants. The swelling agent, which normally swells to several times its original volume in water, exhibits a controlled swelling in the 15 presence of the viscolyzing and/or gelling agent. The swelling agent may be present in an amount from about 3% to about 15% by weight of the total weight of the composition. More preferably, the swelling agent may be present in an amount from about 5% to about 15% by weight of the total weight of the composition. 20 VISCOLYZING AGENT AND GELLING AGENT According to the present invention, the pharmaceutical composition comprises a viscolyzing agent which, upon contact with gastrointestinal fluid, instantaneously viscolyzes to trap the gas generated by the gas generating -14- WO 01/64183 PCT/IBO1/00279 component. Preferably, the viscolyzing agent comprises of a carbohydrate gum, such as xanthan gum. Other examples of carbohydrate gums include tragacanth gum, gum karaya, guar gum, acacia, and the like. Cellulose ethers of moderate to high viscosity, like hydroxypropyl methylcellulose, can also be used. In the 5 present invention, it has been found that xanthan gum helps in maintaining tablet integrity when stirred in an aqueous medium, and in sustaining the release of the drug. According to the present invention, the pharmaceutical composition comprises either said viscolyzing agent or a gelling agent or both. The gelling 10 agent is preferably sodium alginate. The gelling agent cross-links with time to form a stable structure which entraps the generated gas. Thus, with the passage of time, the gelling agent results in a hydrodynamically balanced system whereby the matrix is retained in the stomach for an extended period of time. Simultaneously, the viscolyzing agent and the gelling agent provide a 15 tortuous diffusion pathway for the drug, thereby resulting in controlled drug release. Preferably, the viscolyzing agent and/or the gelling agent are present in an amount from about 0.1% to about 8% by weight of the total weight of the composition. More preferably, the viscolyzing agent and/or the gelling agent are 20 present in an amount from about 0.2% to about 5% by weight of the total weight of the composition. The successful use of even low amounts of a viscolyzing agent and/or gelling agent such as xanthan gum in providing tablet integrity is indeed -15- WO 01/64183 PCT/IBO1/00279 surprising in view of the fact that the pharmaceutical composition of the present invention comprises a gas generating component and a swelling agent which is most frequently employed as a disintegrant. Those skilled in the art can well recognize that both components can result in rapid disintegration of tablets. 5 Tablets containing hydroxypropylcellulose in amounts approximately the same as the amounts of carbohydrate gum in the present invention disintegrate in 10 to 15 minutes when stirred in an acidic medium. Such disintegration can result in a dose dumping effect, i.e., rapid delivery of a large quantity of drug from the system, and is undesirable particularly because controlled drug delivery systems 10 contain several times the amount of drug in a conventional formulation. Granules formed as a result of the disintegration are also emptied from the stomach in a shorter time than intact tablets. The present invention avoids such disintegration with the use of small quantities of a viscolyzing agent, such as a heteropolysaccharide gum, so that tablets or capsules containing a high dose 5 medicament are of an acceptable size to be taken orally. In preferred embodiments of the present invention, the viscolyzing agent is xanthan gum. Xanthan gum, also known as corn sugar gum, is a high molecular weight (ca. 2 x 106) biosynthetic polysaccharide gum produced by a pure-culture aerobic fermentation of a carbohydrate with Xanthomonas 20 campestris. It is extraordinarily enzymatically resistant. In preferred embodiments of the present invention, the xanthan gum has a particle size such that at least 50% by weight passes through a sieve with 44 tm mesh aperture (Sieve No. 325, ASTM). In more preferred embodiments, the -16- WO 01/64183 PCT/IBO1/00279 xanthan gum has a particle size such that all of it passes through a 44 ptm mesh aperture (Sieve No. 325, ASTM). Preferably, the viscolyzing agent is present in an amount from about 0.1 % to about 8%, by weight of the total weight of the composition. More preferably, 5 the viscolyzing agent is present in an amount from about 0.2% to about 5%, by weight of the total weight of the composition. OTHER EXCIPIENTS The pharmaceutical composition may also contain other conventional pharmaceutical excipients, for example, water soluble diluents such as lactose, 0 dextrose, mannitol, sorbitol, and the like; water insoluble diluents such as starch, microcrystalline cellulose, powdered cellulose, and the like; or lubricants such as talc, stearic acid or its salt, magnesium stearate, and the like. PROCESS FOR PREPARATION According to the present invention, the pharmaceutical composition is 5 prepared by mixing the drug with the gas generating component, the swelling agent, and one or both of the viscolyzing agent and the gelling agent, plus other excipients and lubricants. The blend is directly compressed into tablets or may be filled into capsules. Alternatively, the pharmaceutical composition is prepared by mixing the foregoing ingredients with only one-half of the lubricants. The 20 mixture is roll compacted and then sieved to obtain granules. The granules are then mixed with the remaining lubricants, and filled into capsules or compressed into tablets. -17- WO 01/64183 PCT/IBO1/00279 The following table sets forth the various particle size ranges for the cipro floxacin base (determined using a Malvern Master Sizer) used in the examples described below: -18- WO 01/64183 PCT/TBO1/00279 T- 00 C,,i E G E E E 00 0 C0 * (D LOE (PE E E 0 D 6 0 0O N C,, LO c'j E clE LU) C.) eq = (N 0) 0.. PDE cl E OC%4 CNL Cii E E 6o = Mf~ Ml. z LOC E CCi4 CD CD.. - 19 WO 01/64183 PCT/IBO1/00279 COATING According to the present invention, when the pharmaceutical composition is in the form of tablets, it may be coated with a thin layer of a rapidly dissolving water soluble pharmaceutical excipient. A coating of a water soluble excipient 5 results in faster hydration and gas formation than a coating of water soluble polymer and is the preferred coating. Examples of water soluble pharmaceutical excipients include film farmers like cellulose ether polymers, or soluble pharmaceutical diluents like lactose, sucrose, dextrose, mannitol, xylitol, and the like. In a preferred embodiment of 10 the present invention, the water soluble excipient used as a coating is lactose. The tablets may be coated to a weight build-up of about 1% to about 4%, preferably, about 1 % to about 2%. The coating also helps in masking any bitter taste associated with the drug. The present invention is illustrated by, but is by no means limited to, the 15 following examples: EXAMPLE 1 This example illustrates the present invention when the active ingredient is ciprofloxacin hydrochloride. Ciprofloxacin is an example of a drug which is absorbed only from the upper part of the intestine. The pharmaceutical 20 composition is given in Table 1. - 20 - WO 01/64183 PCT/IBO1/00279 TABLE 1 Ingredient Weight (mg/tablet) % w/w Ciprofloxacin hydrochloride monohydrate 598.47 55.16 Xanthan Gum (Keltrol TF) 20.00 1.84 Sodium alginate (Keltone LVCR) 15.00 1.38 Cross-linked carboxymethylcellulose (Ac-Di- 110.00 10.14 Sol) Sodium bicarbonate 230.00 21.20 Microcrystalline cellulose (Avicel PH 101) 16.53 1.52 Sodium Chloride 25.0 2.30 Citric Acid 20.0 1.84 Cross-linked polyacrylic acid (Carbopol 971P) 10.0 0.93 Talc 10.00 0.93 Magnesium Stearate 20.00 1.84 Aerosil 10.00 0.93 Total 1085.00 100% Ciprofloxacin, xanthan gum, sodium alginate, cross-linked carboxymethyl 5 cellulose, sodium bicarbonate, microcrystalline cellulose, sodium chloride, citric acid, and half of the lubricants were mixed together and sieved through a sieve (British Standard Sieve (BSS) No. 44). The blend was compacted on a roll compactor and the compact sieved through a sieve (BSS No. 22) to obtain granules. The granules were mixed with the remaining lubricants and Carbopol 10 and then compressed into tablets. The tablets were spray coated with an aqueous coating composition containing 15.8% w/w lactose, 3.18% w/w talc, and 1.587% w/w titanium dioxide to a weight build up of 1% to 1.5%. The tablets were tested for dissolution in 0.1 N HCI using USP Apparatus 1 with basket speed at 100 rpm. The dissolution results are given in Table 2. - 21 - WO 01/64183 PCT/IBO1/00279 TABLE 2 Time (hrs) Cumulative Percent Release 1 21.16 2 33.22 4 58.72 6 74.6 8 85.83 10 93.58 EXAMPLE 2 5 This example illustrates the present invention when the active ingredient is ciprofloxacin base. The pharmaceutical composition is given in Table 3. TABLE 3 Ingredient Weight % w/w of % w/w (mg/tablet) tablet of drug Ciprofloxacin base 1000.00 71.43 100.0 Xanthan Gum (Keltrol TF) 15.00 1.07 1.5 Sodium alginate (Keltone LVCR) 10.00 0.71 1.0 Cross-linked polyvinylpyrrolidone 150.00 10.71 15.0 (Kollidon CL-M) Sodium bicarbonate 200.00 14.28 20.0 Magnesium Stearate 15.00 1.07 1.5 Talc 10.00 0.71 10.0 Total 1400.00 100 - 0 Ciprofloxacin was sifted through British Standard Sieve (BSS) No. 22. Xanthan gum, sodium alginate, sodium bicarbonate, crospovidone and half the quantities of lubricants, namely, magnesium stearate and talc, were sifted through a sieve (BSS No. 44). All the above mentioned sifted ingredients were 5 blended uniformly, compacted on a roll-compactor and the compacts sifted - 22 - WO 01/64183 PCT/IBO1/00279 through a sieve (BSS No. 18) to obtain granules. Remaining magnesium stearate and talc were sifted through a sieve (BSS No. 60) and blended with above granules and limited proportion of granule fines (finer than BSS No. 60) and then compressed into tablets. The tablets were optionally spray coated with 5 an aqueous coating composition containing 15.8% w/w lactose, 3.18% w/w talc and 1.587% w/w titanium dioxide to a weight build up of 1% to 1.5%. The dissolution results are given in Table 4. TABLE 4 Time (hrs) Cumulative Percent Release 1 24.9 2 37.8 4 60.5 6 80.6 8 85.4 10 98.8 10 EXAMPLE 3 This example illustrates the present invention when the active ingredient is ciprofloxacin hydrochloride. The pharmaceutical composition is given in Table 5. - 23 - WO 01/64183 PCT/IBO1/00279 TABLE 5 Ingredient Weight % w/w (mg/tablet) Ciprofloxacin hydrochloride monohydrate 600.00 61.54 Xanthan Gum (Keltrol TF) 10.00 1.02 Sodium alginate (Keltone LVCR) 25.00 2.57 Cross-linked carboxymethylcellulose (Ac-Di-Sol) 60.00 6.16 Sodium bicarbonate 250.00 25.64 Microcrystalline cellulose (Avicel PH 101) 15.00 1.54 Talc 5.00 0.52 Magnesium Stearate 10.00 1.02 Total 975.00 100% The tablets were prepared as described in Example 1 except that Ac-Di Sol was incorporated extragranularly. Tablets were tested for dissolution as 5 described in Example 1. The dissolution results are given in Table 6. TABLE 6 Time (hrs) Cumulative Percent Release 1 28.16 2 38.32 4 52.37 6 64.03 8 74.23 10 82.80 EXAMPLE 4 10 Gastric Retention and Bioavailability Studies This example demonstrates that tablets prepared according to the present invention are retained for extended periods in the stomach. - 24 - WO 01/64183 PCT/IBO1/00279 The bioadhesive tablet was prepared as a bilayer tablet. The drug layer composition is given in Table 7, and the bioadhesive layer composition is given in Table 8. TABLE 7 Ingredient Weight (mg/tablet) Ciprofloxacin hydrochloride monohydrate 599.99 Hydroxypropylcellulose-L 20.00 Disodium hydrogen phosphate 25.00 Citric Acid 25.00 Talc 7.00 Magnesium Stearate 15.00 Aerosil 200 10.00 Total 701.99 5 TABLE 8 Ingredient Weight (mg/tablet) Hydroxypropyl methylcellulose (Methocel K4M) 215.00 Cross-linked polyacrylic acid (Carbopol 934 P) 75.00 Dicalcium phosphate 145.00 Sodium benzoate 8.00 Talc 2.00 Aerosil-200 2.50 Sunset Yellow 2.50 Total 450.00 The tablets were prepared by conventional steps of mixing, roll compac tion, sieving, blending with the lubricants and compression into bi-layered 10 tablets. 70 mg of barium sulphate was incorporated into the bioadhesive layer to function as x-ray contrast medium. Gastric retention studies of the bio adhesive bi-layered tablets were done on healthy male volunteers who were - 25 - WO 01/64183 PCT/IBO1/00279 given two tablets following a standard breakfast. X-ray images were recorded periodically. The bioadhesive tablets were retained in the stomach for 2.5 to 3.5 h rs. Hydrophilic matrix tablets with the composition given in Table 9 were also 5 prepared. TABLE 9 Ingredient Weight (mg/tablet) Ciprofloxacin hydrochloride monohydrate 599.99 Hydroxypropyl methylcellulose (Methocel K4M) 20.00 Hydroxypropylcellulose-L 40.00 Citric Acid 25.00 Disodium hydrogen phosphate 25.00 Talc 10.00 Magnesium Stearate 10.00 Total 729.99 70mg of barium sulfate was also incorporated into the above composition. 10 The tablets were prepared by conventional steps of mixing, roll compaction, sieving, blending with the lubricants and compression into tablets. Floating capsules with the composition given in Table 10 were also prepared. - 26 - WO 01/64183 PCT/IBO1/00279 TABLE 10 Ingredient Weight (mg/capsule) Ciprofloxacin hydrochloride monohydrate 599.99 Hydroxypropyl methylcellulose 30.00 (Methocel K4M) Hydroxypropylcellulose-L 30.00 Citric Acid 5.00 Disodium hydrogen phosphate 5.00 Talc 4.00 Magnesium Stearate 6.00 Total 679.99 50 mg of barium sulphate was incorporated into the above composition. 5 Gastric retention studies were done on healthy male volunteers who were given two tablets/capsules after a standard breakfast. X-ray images were recorded periodically. The hydrophilic matrix tablets were retained for 2 to 2.5 hrs, and the floating capsules for 3.5 to 4.5 hrs. Gastric retention studies were also done on the ciprofloxacin base 10 formulation of a similar composition as given in Example 2. The volunteers were given two tablets after a standard breakfast. Magnetic resonance imaging confirmed that the tablets according to the present invention were retained in the stomach for a period of 5 to 7 hrs. In another experiment, a randomized, three-treatment, three period, 15 cross-over pilot bioavailability study was conducted for formulation A (two ciprofloxacin hydrochloride 500 mg tablets, for once-daily administration, prepared according to Example 1), formulation B (ciprofloxacin free base 1000 - 27 - WO 01/64183 PCT/IBO1/00279 mg tablets, for once-daily administration, prepared according to Example 2), and reference formulation R (CiproTM (Bayer Corp.) 500 mg immediate release tablets given twice daily). The tablets were administered 30 minutes after a standard breakfast. The mean serum concentration-time profile is given in Figure 1. 5 Figure 1 is based on the following data listed in Table 11, below. TABLE 11 Mean Concentrations mcg/mL) Time (Hr) A B R 0 0.0000 0.0000 0.0000 0.5 * * 0.30000 1 0.0489 0.3720 1.8379 1.5 * * 2.0779 2 0.1557 0.9940 1.8546 2.5 * * 1.6348 3 1.1806 1.5004 1.3731 4 2.7070 2.1164 1.0868 5 2.8478 1.8898 0.7638 6 1.7944 1.3594 0.5404 8 1.2467 0.9494 0.3579 10 0.9367 0.7855 0.2323 12 0.6503 0.8714 0.1687 12.5 * * 0.1594 13 * * 0.3916 13.5 * * 0.8982 14 0.4171 0.6831 1.0993 14.5 * * 1.1432 15 * * 1.3889 16 0.2753 0.4826 1.1187 17 * * 0.9377 18 0.1901 0.3812 0.7633 20 * * 0.4864 22 * * 0.3766 24 0.1039 0.1778 0.2825 A: 500 mg X 2 OD Fed (FDA Meal) B: 1000 mg OD, Fed (FDA Meal) R: 500 mg b.l.d. Fed (FDA Meal) 10 *For OD formulation these sampling points were not included Both the once-daily formulations (A and B) gave an extent of absorption comparable to the immediate release tablets (R). Thus, it can be inferred that - 28 - WO 01/64183 PCT/IBO1/00279 the time period of release of drug into gastric fluid was adjusted such that it was about the same as or less than the retention time of the tablets at the site of absorption. Furthermore, formulation B gave a serum concentration time profile that would be desirable for a once-daily formulation in that the peak serum 5 concentration was comparable to that for the immediate release drug, and the effective serum concentrations of the drug were maintained for longer periods. EXAMPLE 5 In some respects, formulation B of the prior Example did not give as good results as the twice-daily CiproTM 500 mg tablets. For example, the Area Under 10 the Curve above the Minimum Inhibitory Concentration (AUC above MIC) for formulation B was less than that of conventional CiproTM tablets. An improved once-daily 1,000 mg ciprofloxacin free base formulation (the "OD" formulation) was developed, the composition of which is given in Table 12. In the OD formulation, the amount of gelling agent (sodium alginate) is about 15 one-half that of formulation B (0.49% vs. 1.0%). TABLE 12 Ingredients Weight % w/w of the (mg/tablet) drug Ciprofloxacin base 1000.0 69.9 Sodium alginate 5.0 0.34 Xanthan gum 15.0 1.03 Sodium bicarbonate 200.0 13.74 Cross-Linked polyvinyl pyrrolidone 176.8 12.15 (Kollidon CL-M) Magnesium stearate 33.0 2.26 Talc 10.0 0.68 Total 1440 100 - 29 - WO 01/64183 PCT/IBO1/00279 Tablets were prepared from the components in Table 12 and tested for dissolution as described earlier. Remarkably, it was observed that the in vitro 5 dissolution profile of the OD formulation (Table 13) was much faster releasing than formulation B. Thus, more than 80% of the drug in the OD tablets was released within 4 hours as compared to 8 hours for formulation B. Compare Table 12 with Table 13. TABLE 13 Time (hrs.) Cumulative percent Release 1 35.49 2 53.61 4 82.33 6 98.72 10 The mean stomach retention of the OD tablets was studied by magnetic resonance imaging and was found to be 5.33 hours which correlated well with the 6 hour dissolution profile of these tablets. In order to compare the pharmacokinetic and pharmacodynamic para 15 meters of this once daily formulation, a randomized, three period, balanced crossover bioavailability study was conducted in 12 healthy, adult male human subjects, between 18-45 years of age where one dose of ciprofloxacin 1000 mg OD tablets was administered 30 minutes after a standard high fat breakfast. The immediate release CiproTM tablets were tested under both fed and fasted 20 conditions. -30- WO 01/64183 PCT/IBO1/00279 Under fed conditions, two oral doses of 500 mg immediate release CiproTM tablets were given. The first oral dose was given within 30 minutes of a high fat breakfast and the second dose was given 12 hours later after a high fat meal (dinner). 5 Under fasted conditions, two oral doses of 500 mg tablets of the CiproTM immediate release tablets were administered. The first oral dose was given after an overnight fast, and the second oral dose was given 12 hours later but four hours after a light meal. The results of the study are shown in Figs. 2 and 3, where Fig. 2 shows 0 the plasma concentration over time of the OD tablets (fed) vs. CiproTM (fed), and Fig. 3 shows the plasma concentration of the OD tablets (fed) vs. Cipro T M (fasted). Figures 2 and 3 are based on the following data listed in Table 14 and Table 15, respectively, below. - 31 - WO 01/64183 PCT/IBO1/00279 TABLE 14 Mean Concentrations (mcg/mL) Time (Hr) A C 0 0.0000 0.0000 0.5 0.2190 * 1 1.0964 0.3430 1.5 1.9702 * 2 2.0397 0.9751 2.5 1.8232 * 3 1.5617 1.6335 4 1.2265 2.6216 5 1.0123 2.9162 6 0.7777 2.0336 8 0.5291 1.4256 10 0.3527 1.3841 12 0.2608 0.9790 12.5 0.3159 * 13 0.4176 * 13.5 0.8401 * 14 1.9238 0.5942 14.5 1.8384 * 15 1.6543 * 16 1.2336 0.4393 17 0.9689 * 18 0.8258 0.3357 20 0.5962 * 22 0.4366 * 24 0.3653 0.1843 A: 500 mg b.l.d. Fed (FDA Meal) C: 1000 mg OD Fed (FDA Meal) *For OD formulation these sampling points were not included 5 - 32 - WO 01/64183 PCT/IBO1/00279 TABLE 15 Mean Concentrations (mcg/mL) Time (Hr) B C 0 0.0000 0.0000 0.5 1.3580 * 1 2.4747 0.3430 1.5 2.7413 * 2 2.3684 0.9751 2.5 2.0204 * 3 1.5997 1.6335 4 1.1985 2.6216 5 0.9429 2.9162 6 0.7298 2.0336 8 0.5172 1.4256 10 0.3575 1.3841 12 0.2709 0.9790 12.5 0.9855 * 13 2.5113 * 13.5 2.7718 * 14 2.4376 0.5942 14.5 1.9856 * 15 1.7173 * 16 1.1702 0.4393 17 0.8631 * 18 0.7360 0.3357 20 0.5095 * 22 0.4207 * 24 0.3431 0.1843 B: 500 mg b.l.d. Fasting C: 1000 mg OD Fed (FDA Meal) *For OD formulation these sampling points were not included 5 The OD formulation gave a plasma concentration time profile desirable for once daily dosage form in that the peak plasma concentration (Cmax) was comparable to that for the immediate release drug indicating a similar rate of absorption of the drug. The total bioavailability of the drug AUC(O-) (Area Under 10 the Curve) was also comparable to that of immediate release tablets indicating that all of the drug is released from the formulation during its residence time in the stomach. See Table 16. - 33 - WO 01/64183 PCT/IBO1/00279 TABLE 16 Study Cmax (pg/ml) AUC (0 ) (pg.h/ml) Ciprofloxacin 3.04 24.81 1000 mg. OD (Fed) Cipro TM 3.17 26.28 500 mg Bid (Fasted) Cipro TM 2.66 22.39 500 Mg Bid (Fed) Table 17 gives the AUC above MIC at the three levels of 0.1pg/ml, 0.25 5 pg/ml and 0.5 pg/ml for ciprofloxacin OD 1000 mg vs. Cipro T M 500 mg bid. These values for ciprofloxacin OD were better than those for CiproTM immediate release tablets administered twice daily under fed conditions, indicating better therapeutic efficacy of the OD formulation when both immediate and controlled dosage forms were administered after food. The therapeutic efficacy of the OD 10 tablets under fed condition was comparable to the therapeutic efficacy of the CiproTM immediate release tablets administered under fasting conditions. Based on the above results seen in Figures 1, 2, and 3, it is anticipated that a sustained release solid dosage form of ciprofloxacin would have to provide pharmacokinetic performance as measured by mean serum concentration, area 15 under the serum/plasma concentration-time curve above minimum inhibitory concentrations and durations above minimum inhibitory serum/plasma concentrations of at least 70% as compared to immediate release divided dose treatment. While the above results have been specifically identified for 1,000 mg tablets, it is anticipated that 100-1,000 mg tablets of ciprofloxacin, orally 20 administered to humans under fed conditions, would provide a medicament - 34 - WO 01/64183 PCT/IBO1/00279 serum/plasma concentration - time curve with an area under the curve (time zero to infinity), ranging from 3.5 to about 30 pg-hours/ml. Similarly, it is anticipated that the 100 mg-1,000 mg tablets would provide a mean peak serum/plasma concentration ranging from about 0.5 to about 4 pg/ml. Further, 5 it is anticipated that the 100 mg-1,000 mg tablets would provide a medicament serum/plasma concentration - time curve with an area under the curve (above a minimum inhibitory concentration of 0.1 ptg/ml), ranging from about 3 to about 26 ptg-hours/ml. It is also anticipated that the 100 mg-1,000 mg tablets would provide a medicament serum/plasma concentration - time curve with an area 10 under the curve (above a minimum inhibitory concentration of 0.25 pg/ml), ranging from about 2 to about 22 [tg-hours/ml. Finally, it is anticipated that they 100 mg-1,000 mg tablets would provide a medicament serum/plasma concentra tion - time curve with an area under the curve (above a minimum inhibitory concentration of 0.5 pim/ml), ranging from about I to about 18 pig-hours/ml. 5 TABLE 17 AUC above MIC Treatment 0.1 pg/ml.h 0.25 pg/ml.h 0.5 pg/ml.h Ciprofloxacin base 20.7 ± 4.4 17.4 ± 4.3 13.2 ± 4.1 1000 mg, OD (Fed) CiproTM 21.5 ± 3.7 18.0 ±3.8 13.4 ±4.0 2 x 500 mg bid (Fasted) I CiproTM 17.68 ± 3.9 14.2 ± 3.9 9.7 ± 3.4 2 x 500 mg bid (Fed) Thus, a minor change in the percentage of hydrophilic polymer (sodium 20 alginate) from 0.71% w/w of the composition to 0.34% w/w of the composition resulted in a dramatic and unexpected improvement in the pharmacodynamic - 35 - WO 01/64183 PCT/IBO1/00279 and pharmacokinetic parameters, which are important measures of therapeutic efficacy. EXAMPLE 6 This example illustrates the present invention when the active ingredient 5 is ciprofloxacin base: TABLE 18 Ingredient Weight (mg/tablet) % w/w Ciprofloxacin 1012.10 68.53 Xanthan Gum 45.0 3.05 Sodium Bicarbonate 200 13.54 Crospovidone 176.82 11.97 Magnesium Stearate 33 2.23 Talc 10 0.68 Total 1476.92 100 The tablets were prepared as described in Example 2. The tablets were tested for dissolution as described in Example 1. The dissolution results are 10 given in Table 19. TABLE 19 Time (hrs) Cumulative Percent Release 1 34 2 51.4 4 69.0 6 94.8 8 100.5 EXAMPLE 7 This example illustrates the present invention when the active ingredient 15 is ciprofloxacin base: - 36 - WO 01/64183 PCT/IBO1/00279 TABLE 20 Ingredient Weight (mg/tablet) % w/w Ciprofloxacin 1012.10 69.47 Sodium Alginate 25 1.72 Sodium Bicarbonate 200 13.73 Crospovidone 176.82 12.14 Magnesium Stearate 33 2.27 Talc 10 0.69 Total 1456.92 100.02 The tablets were prepared as described in Example 2. The tablets were tested for dissolution as described in Example 1. The dissolution results are 5 given in Table 21. TABLE 21 Time (hrs.) Cumulative Percent Release 1 34.6 2 52 3 68.4 4 79.5 6 92.4 8 95.7 - 37 - WO 01/64183 PCT/IBO1/00279 EXAMPLE 8 This example illustrates the present invention when the active ingredient is ciprofloxacin base: TABLE22 Ingredient Weight (mg/tablet) % w/w Ciprofloxacin 1012.10 69 Sodium Alginate 5.0 0.34 Sodium Bicarbonate 200 13.63 Crospovidone 176.82 12.05 Magnesium Stearate 33 2.25 Talc 10 0.68 Methocel K1 5M 30 2.04 Total 1466.92 99.99 5 The tablets were prepared as described in Example 2. The tablets were tested for dissolution as described in Example 1. The dissolution results are given in Table 23. TABLE 23 Time (hrs.) Cumulative Percent Release 1 43.6 2 57.6 3 74.4 4 87.0 6 97.5 8 100.2 10 -38- WO 01/64183 PCT/IBO1/00279 EXAMPLE 9 This example illustrates the present invention when the active ingredient is ciprofloxacin base: TABLE 24 Ingredient Weight (mg/tablet) % w/w Ciprofloxacin 1015.18 75.15 Sodium Alginate 5.0 0.37 Xanthan Gum 15 1.11 Sodium Bicarbonate 200 14.8 Crospovidone 72.75 5.39 Magnesium Stearate 33 2.44 Talc 10 0.74 Total 1350.93 100 5 The tablets were prepared as described in Example 2. The tablets were tested for dissolution as described in Example 1. The dissolution results are given in Table 25. TABLE 25 Time (hrs.) Cumulative Percent Release 1 39.2 2 54.2 3 72.39 4 84.9 6 100.29 10 EXAMPLE 10 This example illustrates the present invention when the active ingredient is ciprofloxacin base: - 39 - WO 01/64183 PCT/IBO1/00279 TABLE 26 Ingredient Weight (mg/tablet) % w/w Ciprofloxacin 1015.18 67.35 Sodium Alginate 5.0 0.33 Xanthan Gum 15 1.0 Crospovidone 176.82 11.73 Magnesium Stearate 33 2.19 Talc 10 0.66 Sodium Carbonate 252.32 16.74 Total 1507.32 100 The tablets were prepared as described in Example 2. The tablets were tested for dissolution as described in Example 1. The dissolution results are 5 given in Table 27. TABLE 27 Time (hrs.) Cumulative Percent Release 1 31.34 2 59.86 3 75.3 4 81.69 6 90.39 8 91.5 EXAMPLE 11 This example illustrates the present invention when the active ingredient 10 is ciprofloxacin base: -40- WO 01/64183 PCT/IBO1/00279 TABLE 28 Ingredient Weight (mg/tablet) % w/w Ciprofloxacin 1015.18 69.66 Sodium Alginate 7.28 0.5 Xanthan Gum 15 1.03 Sodium Bicarbonate 200 13.72 Crospovidone 176.82 12.13 Magnesium Stearate 33 2.26 Talc 10 0.69 Total 1457.28 99.99 The tablets were prepared as described in Example 2. The tablets were tested for dissolution as described in Example 1. The dissolution results are 5 given in Table 29. TABLE 29 Time (hrs.) Cumulative Percent Release 1 40.06 2 59.26 3 86.19 4 96.39 6 100.2 EXAMPLE 12 This example illustrates the present invention when the active ingredient 10 is ciprofloxacin base: -41 - WO 01/64183 PCT/IBO1/00279 TABLE 30 Ingredient Weight % w/w (mg/tablet) Ciprofloxacin 1015.18 70.43 Sodium Alginate 5.0 0.35 Xanthan Gum 1.46 0.1 Sodium Bicarbonate 200 13.87 Crospovidone 176.82 12.27 Magnesium Stearate 33 2.29 Talc 10 0.69 Total 1441.46 100 The tablets were prepared as described in Example 2. The tablets were tested for dissolution as described in Example 1. The dissolution results are 5 given in Table 31. TABLE 31 Time (hrs.) Cumulative Percent Release 1 33.34 2 58.94 3 76.11 4 83.91 6 95.7 EXAMPLE 13 10 This example illustrates the present invention when the active ingredient is ciprofloxacin base: -42 - WO 01/64183 PCT/IBO1/00279 TABLE 32 Ingredient Weight (mg/tablet) % w/w Ciprofloxacin 1015.18 69.44 Sodium Alginate 5.0 0.34 Xanthan Gum 21.83 1.5 Sodium Bicarbonate 200 13.68 Crospovidone 176.82 12.1 Magnesium Stearate 33 2.26 Talc 10 0.68 Total 1461.83 100 The tablets were prepared as described in Example 2. The tablets were 5 tested for dissolution as described in Example 1. The dissolution results are given in Table 33. TABLE 33 Time (hrs.) Cumulative Percent Release 1 44.2 2 61.86 3 87.9 4 98.7 6 106.95 EXAMPLE 14 10 This example illustrates the present invention when the active ingredient is ciprofloxacin base: -43 - WO 01/64183 PCT/IBO1/00279 TABLE 34 Ingredient Weight (mg/tablet) % w/w Ciprofloxacin 1016.19 72.51 Sodium Alginate 5.0 0.36 Xanthan Gum 15 1.07 Sodium Bicarbonate 145.5 10.38 Crospovidone 176.82 12.61 Magnesium Stearate 33 2.35 Talc 10 0.71 Total 1401.51 99.99 The tablets were prepared as described in Example 2. The tablets were tested for dissolution as described in Example 1. The dissolution results are 5 given in Table 35. TABLE 35 Time (hrs.) Cumulative Percent Release 1 44.46 2 56.8 3 65.91 4 74.19 6 89.31 8 98.49 Table 36 below summarizes Examples 5-14 above with respect to their ingredients and includes the dissolution profile of each formulation. 10 -44 - WO 01/64183 PCT/TBO1/00279 C ~ C Cl 0 c t o Lfi T 0 C 6 (0 C) mo LOr- rl- 'Ct CTQD0) (D-CQ CN C) 77 CD C.0 ) mCL N.- ) OT- - ( C:) N V- cO) 0.) 1 CO N Coo 0)0)6Co o-) c C c (D)C~ CD CY or- C:- m a - 00c? o m ) I C) COC (.6j C) 0 ) Co 0)05 E Z z c 0Lyi~ Cu Co M- C LONr- M0M M .E LO -N- 0) CYo 0) C:. Loco m ) I- 0 j. : m0 co ~ j 1 CO mr C) ( ) " oc tC)V CU 3 Co ~C Co C,4 z C rZ 4 lOr_. co z It U' U_000 co U' a - It co C:Z0) O IOLE co0)0 COCOZ o o -) ( mC N C ) co~ 0 0) rl 7 ) CfO L 0. C: c o 6 -<0 C) C'L U'). 000 ~0 (U(U c I C) co -~ O1) 2 -co= (U 0> 4- 0 0 5~ 45 - WO 01/64183 PCT/IBO1/00279 EXAMPLE 15 This example illustrates the present invention when the active ingredient is ciprofloxacin base: TABLE 37 5 Ingredient Weight (mg/tablet) % w/w Ciprofloxacin 1015.18 67.98 Sodium Alginate 5.0 0.003 Xanthan Gum 15.0 0.01 Crospovidone 176.82 11.84 Mag. Stearate 33.0 2.21 Talc 10.0 0.67 Calcium Carbonate 238.27 15.96 Total 1493.27 98.673 The tablets were prepared as described in Example 2. The tablets were tested for dissolution as described in Example 1. The dissolution results are given in Table 38. 10 TABLE38 Time (hrs.) Cumulative Percent Release 1 44.4 2 62.4 3 73.11 4 78.0 6 84.09 8 87.0 -46- WO 01/64183 PCT/IBO1/00279 EXAMPLE 16 This example illustrates the present invention when the active ingredient is ciprofloxacin base: TABLE39 5 Ingredient Weight (mg/tablet) % w/w Ciprofloxacin 1015.18 69.32 Sodium Alginate 14.55 0.009 Xanthan Gum 15.0 0.01 Sod. Bicarbonate 200.0 13.66 Crospovidone 176.82 12.07 Magnesium Stearate 33.0 2.25 Talc 10.0 0.68 TOTAL 1464.55 97.32 The tablets were prepared as described in Example 2. The tablets were tested for dissolution as described in Example 1. The dissolution results are given in Table 40. 10 TABLE40 Time (hrs.) Cumulative Percent Release 1 37.9 2 45.06 3 65.91 4 71.1 6 78.81 -47- WO 01/64183 PCT/IBO1/00279 EXAMPLE 17 This example illustrates the present invention when the active ingredient is ciprofloxacin base: TABLE 41 5 Ingredient Weight (mg/tablet) % w/w Ciprofloxacin 1015.18 67.11 Sodium Alginate 5.0 0.003 Xanthan Gum 72.75 4.81 Sodium Bicarbonate 200.0 13.22 Crospovidone 176.82 11.69 Magnesium Stearate 33.0 2.18 Talc 10.0 0.006 TOTAL 1512.75 99.019 The tablets were prepared as described in Example 2. The tablets were tested for dissolution as described in Example 1. The dissolution results are given in Table 42. 10 TABLE42 Time (hrs.) Cumulative Percent Release 1 32.26 2 47.2 3 63.3 4 74.01 6 94.2 Other than the above experiments, the following formulations were made into tablets as described above. Dissolution and floating characteristics testing -48 - WO 01/64183 PCT/IBO1/00279 was also done for the following formulations. One or the other, i.e., the dissolution profile or floating characteristics, were found to be unsatisfactory in comparison to the above examples, for tablets according to the following formulations: 5 TABLE43 Ingredient Example 18 Example 19 Ciprofloxacin 1015.18 1015.18 Sodium Alginate 0 5.0 Xanthan Gum 15.0 0 Sodium Bicarbonate 200.0 200.0 Crospovidone 176.82 176.82 Magnesium Stearate 33.0 33.0 Talc 10.0 10.0 TOTAL 1450.00 1440.0 DISSOLUTION Time (hrs.) Cumulative Percent Release 1 68.8 52.5 2 93.2 68.94 3 104.1 90.39 4 - 100.8 6 104.79 8 - 49 - WO 01/64183 PCT/IBO1/00279 TABLE 44 Ingredients Example Example Example Example Example 20 21 22 23 24 Ciprofloxacin 1016.19 1016.19 1012.1 1016.19 1012.1 Sodium Alginate 5.0 5.0 5.0 5.0 5.0 Sodium 200.0 200.0 200.0 200.0 200.0 Bicarbonate Crospovidone 176.82 176.82 176.82 176.82 176.82 Magnesium 33.0 33.0 33.0 33.0 33.0 Stearate Talc 10.0 10.0 10.0 10.0 10.0 Methocel K15M 15.0 - - - Gellan Gum - 15.0 30.0 - (Gelrite) Carrageenan - - - 15.0 45.0 TOTAL 1456.01 1456.01 1466.92 1456.01 1481.92 DISSOLUTION Time (hrs.) Cumulative Percent Release 1 48.66 50.74 49.6 72.46 88.8 2 63.54 62.86 58.2 81.54 93.2 3 80.31 74.19 67.2 87.09 97.8 4 89.49 80.79 74.4 92.1 99.0 6 100.11 91.71 88.2 96.45 100.2 8 101.7 99.99 95.1 97.11 101.1 -50- WO 01/64183 PCT/IBO1/00279 TABLE 45 Ingredients Example Example Example Example Example Example 25 26 27 28 29 30 Ciprofloxacin 1015.18 1012.1 1015.18 1012.1 1015.18 1012.1 Xanthan Gum 15.0 15.0 15.0 15.0 15.0 15.0 Sodium 200.0 200.0 200.0 200.0 200.0 200.0 Bicarbonate Crospovidone 176.82 176.82 176.82 176.82 176.82 176.82 Magnesium 33.0 33.0 33.0 33.0 33.0 33.0 Stearate Talc 10.0 10.0 10.0 10.0 10.0 10.0 Carbopol 971 P 5.0 10.0 - - - Methyl Cellulose - - 5.0 20.0 Eudragit EPO - - - - 5.0 30.0 TOTAL 1455.0 1446.92 1455.0 1456.92 1455.0 1466.92 DISSOLUTION Time (hrs.) Cumulative Percent Release 1 45.2 56.8 74.26 68.2 94.26 101.4 2 59.34 67.0 87.06 83.0 94.94 3 71.79 76.8 95.61 92.4 97.89 4 80.91 84.9 97.71 95.4 98.79 6 92.01 95.1 99.21 99.0 - 8 93.0 97.5 100.59 100.8 - -51 - WO 01/64183 PCT/IBO1/00279 TABLE 46 Ingredient Example Example Example Example Example Example 31 32 33 34 35 36 Ciprofloxacin 1015.18 1012.1 1015.18 1012.1 1015.18 1012.1 Sodium Alginate 5.0 5.0 5.0 5.0 5.0 5.0 Xanthan Gum 15.0 15.0 15.0 15.0 15.0 15.0 Sodium 200.0 200.0 200.0 200.0 200.0 200.0 Bicarbonate Magnesium 33.0 33.0 33.0 33.0 33.0 33.0 Stearate Talc 10.0 10.0 10.0 10.0 10.0 10.0 Ac-di-sol 176.82 100.0 - - - Sodium Starch - - 176.82 125.0 - glycolate MCC (Avicel pH - - - - 176.82 125.0 101) TOTAL 1455.0 1375.1 1455.0 1400.1 1455.0 1400.1 DISSOLUTION Time (hrs.) Cumulative Percent Release 1 42.86 47.6 57.46 53.8 67.4 62.6 2 51.4 55.8 65.6 62.4 79.26 74.4 3 60.21 62.4 72.81 70.8 86.7 84.9 4 66.81 67.5 77.19 75.6 91.5 88.2 6 81.09 76.2 84.69 82.4 95.49 94.8 8 87.6 83.1 92.31 88.2 98.79 97.2 -52- WO 01/64183 PCT/IBO1/00279 TABLE 47 Ingredient Example Example Example 37 38 39 Ciprofloxacin 1015.18 1015.18 1015.18 Sodium Alginate 5.0 5.0 5.0 Xanthan Gum 15.0 15.0 15.0 Sodium Bicarbonate 200.0 200.0 200.0 Crospovidone 0 261.9 363.75 Magnesium Stearate 33.0 33.0 33.0 Talc 10.0 10-.0 10.0 TOTAL 1278.18 1540.08 1641.93 DISSOLUTION Time (hrs.) Cumulative Percent Release 1 66.66 49.2 57.26 2 79.8 75.66 77.74 3 91.2 96.99 106.2 4 94.71 100.71 6 97.59 -53- WO 01/64183 PCT/IBO1/00279 TABLE 48 Ingredients Example Example Example 40 41 42 Ciprofloxacin 1016.19 1016.19 1016.19 Sodium Alginate 5.0 5.0 5.0 Sodium Bicarbonate 200.0 200.0 200.0 Crospovidone 176.82 176.82 176.82 Magnesium Stearate 33.0 33.0 33.0 Talc 10.0 10.0 10.0 Methocel K15M 15.0 - Gellan gum (Gelrite) - 15.0 Carrageenan - - 15.0 TOTAL 1456.01 1456.01 1456.01 DISSOLUTION Time (hrs.) Cumulative Percent Release 1 48.66 50.74 72.46 2 63.54 62.86 81.54 3 80.31 74.19 87.09 4 89.49 80.79 92.1 6 100.11 91.71 96.45 8 101.7 99.99 97.11 -54- WO 01/64183 PCT/IBO1/00279 TABLE 49 Ingredients Example Example Example 43 44 45 Ciprofloxacin 1015.18 1015.18 1015.18 Xanthan Gum 15.0 15.0 15.0 Sodium Bicarbonate 200.0 200.0 200.0 Crospovidone 176.82 176.82 176.82 Magnesium Stearate 33.0 33.0 33.0 Talc 10.0 10.0 10.0 Carbopol 971 P 5.0 - Methyl Cellulose - 5.0 Eudragit EPO - - 5.0 TOTAL 1455.01 1455.01 1455.01 DISSOLUTION Time (hrs.) Cumulative Percent Release 1 45.2 74.26 94.26 2 59.34 87.06 94.94 3 71.79 95.61 97.89 4 80.91 97.71 98.79 6 92.01 99.21 8 93.0 100.59 -55- WO 01/64183 PCT/IBO1/00279 TABLE 50 Ingredients Example Example Example 46 47 48 Ciprofloxacin 1015.18 1015.18 1015.18 Sodium Alginate 5.0 5.0 5.0 Xanthan Gum 15.0 15.0 15.0 Sodium Bicarbonate 200.0 200.0 200.0 Magnesium Stearate 33.0 33.0 33.0 Talc 10.0 10.0 10.0 Ac-di-sol 176.82 - Sodium Starch glycolate - 176.82 MCC (Avicel pH 101) - 176.82 TOTAL 1455.0 1455.0 1455.0 DISSOLUTION Time (hrs.) Cumulative Percent Release 1 42.86 57.46 67.4 2 51.4 65.6 79.26 3 60.21 72.81 86.7 4 66.81 77.19 91.5 6 81.09 84.69 95.49 8 87.6 92.31 98.79 -56- WO 01/64183 PCT/IBO1/00279 TABLE 51 Ingredients Example 49 Ciprofloxacin 1015.18 Sodium Alginate 5.0 Xanthan Gum 15.0 Crospovidone 176.82 Magnesium Stearate 33.0 Talc 10.0 Potassium Bicarbonate 238.34 TOTAL 1493.34 DISSOLUTION Time (hrs.) Cumulative Percent Release 1 69.06 2 77.74 3 85.2 4 87.0 6 87.0 8 98.1 - 57 - WO 01/64183 PCT/IBO1/00279 TABLE 52 Ingredient Example 50 Example 51 Ciprofloxacin 1015.18 1015.18 Sod. Alginate 0 1.46 Xanthan Gum 15.0 15.0 Sodium Bicarbonate 200.0 200.0 Crospovidone 176.82 176.82 Magnesium Stearate 33.0 33.0 Talc 10.0 10.0 TOTAL 1450.00 1451.46 DISSOLUTION Time (hrs.) Cumulative Percent Release 1 68.8 51.46 2 93.2 65.34 3 104.1 84.39 4 - 92.79 6 97.41 - 58 - WO 01/64183 PCT/IBO1/00279 TABLE 53 Ingredient Example 52 Ciprofloxacin 1015.18 Sodium Alginate 5.0 Sodium Bicarbonate 200.0 Crospovidone 176.82 Magnesium Stearate 33.0 Talc 10.0 TOTAL 1440.0 DISSOLUTION Time (hrs.) Cumulative Percent Release 1 52.5 2 68.94 3 90.39 4 100.8 6 104.79 - 59 - WO 01/64183 PCT/IBO1/00279 TABLE 54 Ingredient Example 53 Example 54 Example 55 Example 56 Ciprofloxacin 1015.18 1016.19 1015.18 1015.18 Sodium Alginate 5.0 5.0 5.0 5.0 Xanthan Gum 15.0 15.0 15.0 15.0 Sodium Bicarbonate 0 72.75 291.0 436.5 Crospovidone 176.82 176.82 176.82 176.82 Magnesium Stearate 33.0 33.0 33.0 33.0 Talc 10.0 10.0 10.0 10.0 TOTAL 1255.0 1328.76 1546.0 1691.5 DISSOLUTION Time (hrs) % released 1 73.06 50.86 49.0 42.46 2 73.7 63.6 72.14 74.66 3 - 73.89 96.3 96.6 4 94.8 83.7 103.8 104.1 6 87.9 93.51 - 8 - 98.19 While the invention has been described by reference to specific examples, this was for purposes of illustration only. Numerous alternative 5 embodiments will be apparent to those skilled in the art and are considered to be within the scope of the invention. - 60 -

Claims (43)

1. A once daily tablet formulation for oral administration in humans for the controlled release of ciprofloxacin comprising a pharmaceutically effective amount of ciprofloxacin, from about 0.1% to about 8.0% of a viscolyzing agent and/or a gelling agent, about 5.0% to about 15% of a gas generating agent, and about 3.0% to about 15% of a swelling agent, said percentages being w/w of the composition.

2. A once daily tablet formulation for oral administration in humans for the controlled release of ciprofloxacin comprising a pharmaceutically effective amount of ciprofloxacin, from about 0.2% to about 5.0% of a viscolyzing agent and/or a gelling agent, about 5.0% to about 15% of a gas generating agent, and about 5.0% to about 15% of a swelling agent, said percentages being w/w of the composition.

3. The formulation of claim I or 2, wherein the viscolyzing agent is either a carbohydrate gum or cellulose ethers.

4. The formulation of claim 3, wherein the carbohydrate gum is xanthan gum and the cellulose ether is hydroxypropyl methylcellulose. (methocel).

5. The formulation of claim 1 or 2, wherein the gelling agent is sodium alginate. - 61 - WO 01/64183 PCT/IBO1/00279

6. The formulation of claim 1 or 2, wherein either or both the viscolyzing agent and gelling agent are used.

7. The formulation of claim 6, wherein the viscolyzing agent is xanthan gum.

8. The formulation of claim 3, wherein the gas generating agent is selected from the group consisting of sodium bicarbonate, calcium carbonate, sodium carbonate, and mixtures thereof.

9. The formulation of claim 3, wherein the swelling agent is crosslinked polyvinylpyrrolidone.

10. A once daily formulation for oral administration in humans for the controlled release of ciprofloxacin comprising a pharmaceutically effective amount of ciprofloxacin, about 0.2% to about 0.5% sodium alginate, about 0.5 to about 2.0% xanthan gum, about 10.0% to about 25% sodium bicarbonate, and about 5.0% to about 20% cross-linked polyvinylpyrrolidone, said percentages being w/w of the composition, wherein the weight ratio of sodium alginate to xanthan gum is between about 1:1 to about 1:10.

11. The formulation of claim 10 comprising 69.9% ciprofloxacin base, 0.34% sodium alginate, 1.03% xanthan gum, 13.7% sodium - 62 - WO 01/64183 PCT/IBO1/00279 bicarbonate, 12.1% cross-linked polyvinylpyrrolidone, and optionally other pharmaceutical excipients.

12. The formulation of claim 10 in the form of a tablet.

13. A once daily homogenous, single layer tablet formulation for oral administration in humans for the controlled release of ciprofloxacin in the stomach or upper part of the small intestine comprising a pharma ceutically effective amount of ciprofloxacin, about 0.2% to about 0.5% sodium alginate, about 0.5 to about 2.0% xanthan gum, about 10.0% to about 25% sodium bicarbonate, and about 5.0% to about 20% cross-linked polyvinylpyrrolidone, said percentages being w/w of the composition, wherein the weight ratio of sodium alginate to xanthan gum is between about 1:1 to about 1:10.

14. The formulation of claim 13 comprising 69.9% ciprofloxacin base, 0.34% sodium alginate, 1.03% xanthan gum, 13.7% sodium bicarbonate, 12.1% cross-linked polyvinylpyrrolidone, and optionally other pharmaceutical excipients.

15. A once daily tablet formulation for oral administration in humans for the controlled release of ciprofloxacin in the stomach or upper part of the small intestine comprising a pharmaceutically effective amount of ciprofloxacin, about 0.2% to about 0.5% sodium alginate, about 0.5 to about 2.0% xanthan gum, about 10.0% to about 25% sodium - 63 - WO 01/64183 PCT/IBO1/00279 bicarbonate, and about 5.0% to about 20% cross-linked polyvinyl pyrrolidone, said percentages being w/w of the composition, wherein the weight ratio of sodium alginate to xanthan gum is between about 1:1 to about 1:10, said ingredients present in said relative proportions in a single layer.

16. The formulation of claim 15 comprising 69.9% ciprofloxacin base, 0.34% sodium alginate, 1.03% xanthan gum, 13.7% sodium bicarbonate, 12.1% cross-linked polyvinylpyrrolidone, and optionally other pharmaceutical excipients.

17. The formulation of claim 15 in the form of a tablet.

18. A once daily tablet formulation for oral administration in humans for the controlled release of ciprofloxacin in the stomach or upper part of the small intestine comprising a pharmaceutically effective amount of ciprofloxacin, about 0.2% to about 0.5% sodium alginate, about 0.5 to about 2.0% xanthan gum, about 10.0% to about 25% sodium bicarbonate, and about 5.0% to about 20% cross-linked polyvinyl pyrrolidone, said percentages being w/w of the composition, wherein the weight ratio of sodium alginate to xanthan gum is between about 1:1 to about 1:10.

19. The formulation of claim 18 comprising 69.9% ciprofloxacin base, 0.34% sodium alginate, 1.03% xanthan gum, 13.7% sodium - 64 - WO 01/64183 PCT/IBO1/00279 bicarbonate, 12.1% cross-linked polyvinylpyrrolidone, and optionally other pharmaceutical excipients.

20. The formulation of claim 18 in the form of a tablet.

21. A sustained release formulation comprising ciprofloxacin which releases more than 50% of the drug in less than 4 hours and releases more than 60% of the drug in less than 8 hours.

22. A sustained release formulation which releases more than 50% of the drug within about 2-4 hours and releases more than 60% of the drug within about 4-8 hours.

23. The formulation of claim 22, suitable for once-a-day profile.

24. The formulation of claim 23 in the form of a tablet or a capsule.

25. The formulation of claim 24 in the form of a tablet which is coated with a pharmaceutically acceptable excipient.

26. A sustained release formulation comprising 100-1000 mg of ciprofloxacin and pharmaceutically acceptable excipients, wherein the total weight of the dosage unit is less than 2000 mg.

27. The formulation of claim 26 wherein the pharmaceutically acceptable excipients comprises a viscolyzing agent and/or a gelling agent, a gas generating component, and a swelling agent. - 65 - WO 01/64183 PCT/IBO1/00279

28. The formulation of claim 27, which comprises from about 0.1% to about 8.0% of a viscolyzing agent and/or a gelling agent, about 5.0% to about 15% of a gas generating agent, and about 3.0% to about 15% of a swelling agent, said percentages being w/w of the composition.

29. The formulation of claim 28, which comprises from about 0.2% to about 5.0% of a viscolyzing agent and/or a gelling agent, about 5.0% to about 15% of a gas generating agent, and about 5.0% to about 15% of a swelling agent, said percentages being w/w of the composition.

30. The formulation of claim 29, wherein the viscolyzing agent is either xanthan gum or hydroxypropyl methylcellulose (methocel) and the gelling agent is sodium alginate.

31. The formulation of claim 30, wherein both the viscolyzing agent and sodium alginate are used.

32. The formulation of claim 31, wherein the viscolyzing agent is xanthan gum.

33. The formulation of claim 28, wherein the gas generating agent is selected from the group consisting of sodium bicarbonate, calcium carbonate, sodium carbonate and mixtures thereof.

34. The formulation of claim 28, wherein the swelling agent is crosslinked polyvinylpyrrolidone. - 66 - WO 01/64183 PCT/IBO1/00279

35. The formulation of claim 26 which is suitable for once-a-day profile.

36. The formulation of claim 26 in the form of tablet or capsule.

37. The formulation of claim 26 in the form of a tablet which is coated with a pharmaceutically acceptable excipient.

38. A sustained release solid dosage form of ciprofloxacin which, when orally administered in humans under fed conditions, provides mean peak serum/plasma concentration, area under the serum/plasma concentration-time curve above minimum inhibitory concentrations and durations above minimum inhibitory serum/plasma concentrations, of not less than 70% when compared with respect to divided doses of equivalent amount of conventional immediate release ciprofloxacin solid dosage form.

39. The sustained release solid dosage form of claim 38 which, when orally administered in humans under fed conditions, provides a medicament serum/plasma concentration - time curve with an area under the curve, time zero to infinity, ranging from about 3.5 to about 30 ptg-hours/ml.

40. The sustained release solid dosage form of claim 38 which, when orally administered in humans under fed conditions, provides a mean - 67 - WO 01/64183 PCT/IBO1/00279 peak serum/plasma concentration ranging from about 0.5 to about 4 tg/ml.

41. The sustained release solid dosage form of claim 38 which, when orally administered in humans under fed conditions, provides a medicament serum/plasma concentration - time curve with an area under the curve above a minimum inhibitory concentration of 0.1 pig/ml, ranging from about 3 to about 26 tg-hours/ml.

42. The sustained release solid dosage form of claim 38 which, when orally administered in humans under fed conditions, provides a medicament serum/plasma concentration - time curve with an area under the curve above a minimum inhibitory concentration of 0.25 ptg/ml, ranging from about 2 to about 22 pg-hours/ml.

43. The sustained release solid dosage form of claim 38 which, when orally administered in humans under fed conditions, provides a medicament serum/plasma concentration - time curve with an area under the curve above a minimum inhibitory concentration of 0.5 pg/ml, ranging from about 1 to about 18 pig-hours/ml. - 68 -